Chinese Biosimilars Firm 3SBio Reports Positive Second Quarter

3SBio, the first Chinese biotechnology company to list on NASDAQ, reported strong second-quarter earnings for its lead EPO and thrombopoietin products and is on track to launch a pre-filled syringe EPO product in China by year-end, the firm announced Aug. 8